ISHL 14 International Symposium on Hodgkin Lymphoma

Program at a Glance (This Version: September 2026)

Saturday (03.10.2026)

08:30-11:00 **EHA-LYG/GHSG Joint Session: EHA Clinical Practice Guidelines in Lymphoid Malignancies - From Recommendations to Patient Care** *(Chairs: I. Aurer, B. v. Tresckow)*

- Large B-cell lymphomas *(S. Leppä)*
- Mantle cell lymphoma *(I. Aurer)*
- Follicular lymphoma *(K. Linton)*
- HIV-related lymphomas *(M. Hentrich)*
- Peripheral T-cell lymphoma *(F. d'Amore)*
- New Therapeutic Concepts and Horizons in Lymphoma *(C. Diefenbach)*

08:30-11:00 🔒 **Workshop ctDNA in HL** *(Chairs: S. Alig, S. Borchmann, M. Pirosa, C. Steidl)*

Separate Registration Required

🔒 **Workshop by ILROG: Individualization of Radiation Therapy for Hodgkin Lymphoma** *(Chairs: H. T. Eich, J. Yahalom)*

Break

11:30-13:00 **Moving Targets: Rethinking Cellular Therapy Delivery in Aggressive B-Cell Lymphomas** *by Miltenyi Biomedicine GmbH (Chair: B. v. Tresckow)*

- R/R DLBCL Treatment Landscape *(G. Salles)*
- Difficult-to-Treat Patients in R/R DLBCL *(I. Aurer)*
- CAR-T Delivery and Treatment Timing: Clinical Challenges and Opportunities *(B. v. Tresckow)*
- Future Directions in Cellular Therapy *(A. Sureda)*

Break

13:15-14:45 **Early Stages** *(Chairs: C. Diefenbach, H. T. Eich)*

- Personalized RTx: Focus on RTx Techniques and Late Effect Prediction Models *(D. Cutter)*
- Just PD-1 Inhibition? Early Insights from the GHSG INDIE Trial *(P. Bröckelmann)*
- Debate: Should Novel Agents Be Integrated into the Frontline Treatment of Early-Stage Low Risk HL Patients? *(G. Collins, C. Diefenbach)*
- Oral Abstract Presentations

Break

15:00-16:30 **Raising the bar in cHL: From frontline treatment to long-term impact by Bristol Myers Squibb** *by Bristol Myers Squibb (Chair: P. Borchmann, S. Castellino, A. Herrera)*

- The current treatment landscape and challenges in cHL *(P. Borchmann)*
- Current and emerging frontline treatment strategies in adult and elderly patients with cHL *(A. Herrera)*
- How we treat advanced stage frontline cHL - N-AVD vs BrECADD *(P. Borchmann, S. Castellino, A. Herrera)*
- Current and emerging frontline and R/R treatment strategies in pediatric patients with cHL *(S. Castellino)*

Break

17:00-18:30
Opening Ceremony and Award Ceremony
Keynote Lecture: Changing Treatment Paradigms in B-cell Lymphoma *(G. Salles)*

18:30-20:00
Poster Session & Welcome Reception

Sunday (04.10.2026)

08:00-09:15 **HL in Children & Adolescents** *(Chairs: J. Flerlage, C. Mauz-Körholz)*

- Treatment Evolution in Pediatric Hodgkin Lymphoma: From Research to Real-World Impact *(M. Mascarin)*
- Precision Medicine in Pediatric HL/Harmonized Pediatric HL Protocol in South Africa *(J. Geel)*
- Oral Abstract Presentations

Break

09:30-10:30 **New concepts for the treatment of B-cell lymphomas** *by MSD Sharp & Dohme GmbH (Chair: B. v. Tresckow)*

- DLBCL - The current and future role of ADCs in the context of T-cell engaging therapies *(B. Chapuy)*
- cHL - Treatment strategies for PD-1 inhibition in the relapsed/refractory setting *(B. v. Tresckow)*

Break

10:45-12:00 **Translating ctDNA into Clinical Routine** *(Chairs: S. Borchmann, M. Shipp)*

- Circulating Tumor DNA: New Insights from the SWOG S1826 Study *(M. Shipp)*
- Circulating Tumor DNA Analysis for Classification and MRD Assessment - Experience of the German Hodgkin Study Group *(S. Borchmann)*
- Workshop Report *(C. Steidl)*
- Oral Abstract Presentations

Break

12:15-13:30 **Biology & Pathology** *(Chairs: W. Klapper, C. Steidl)*

- The Biology of HRS Cells *(R. Küppers)*
- Novel Insights into the Microenvironment of Hodgkin Lymphoma *(T. Aoki)*
- Oral Abstract Presentations

Break

13:45-15:15 **From Evidence to Experience: How Long-Term and Real-World Data for ADCETRIS® (brentuximab vedotin) May Inform Frontline Practice in Advanced Hodgkin Lymphoma** *by Takeda Pharmaceuticals USA, Inc. (Chair: B. v. Tresckow)*

- Enhancing Frontline Management in Advanced HL with BrECADD *(O. Balocchi)*
- Advancing HL Control and Fertility Preservation with BrECADD *(E. J. Dann)*
- Optimizing Care in High-Risk HL with A+AVD *(C. Burton)*

Break

15:30-17:00 **Living Beyond Lymphoma** *(Chairs: M. Büttner, A. Fosså)*

- Evaluating Late Effects of Contemporary Treatments - Competing Risks & Novel Approaches *(C. Dietrich)*
- Uncertainties with Anti-PD-1 & irAE in the First-Line Setting *(P. Bröckelmann)*
- In Conversation with GHSG Patient Representatives: Building a Bridge Between Cancer Treatment and Everyday Life - Challenges After Lymphoma *(K. Behringer, GHSG Patient Representatives)*
- Oral Abstract Presentations

17:00-18:30 **Advanced Stages** *(Chairs: P. Armand, G. Collins, M. Hertzberg)*

- Unmet Needs and Future Perspectives with:
  - BrECADD: Improving Outcomes of HD21 *(J. Ferdinandus)*
  - Nivo-AVD: Unanswered Questions from SWOG S1826 *(A. Herrera)*
- Oral Abstract Presentations

08:00-10:00 🔒 **Workshop Grassroot Initiative in Classic Hodgkin Lymphoma** *(Chairs: R. Advani, P. Borchmann, P. Oyiro Omondi)*

Separate Registration Required

Monday (05.10.2026)

08:00-09:15 **Special Cases & Situations** *(Chairs: P. Bröckelmann, J. Zijlstra)*

- HL in Pregnancy *(A. S. Robertz)*
- Critical Organ Failure at Presentation *(H. Tharmaseelan)*
- Anti-PD-1 Tx in Pre-Existing Autoimmune Disease *(Y. Jauw)*
- Workshop Report "Grassroot Initiative in Classic Hodgkin Lymphoma" *(R. Advani, P. Oyiro Omondi)*

Break

09:30-10:30 **NLPHL** *(Chairs: R. Hoppe, W. Klapper)*

- Clinical Implications of Growth Patterns *(D. Eichenauer)*
- Treatment Strategies *(J. Flerlage)*
- Oral Abstract Presentations

Break

10:45-12:15 **Relapsed & Refractory HL** *(Chairs: C. H. Moskowitz, A. Sureda)*

- 2L Treatment of HL in the Era of Novel Agents *(A. Moskowitz)*
- Revisiting the Role of Stem Cell Transplantation in rrHL *(B. v. Tresckow)*
- Unmet Needs and Novel Treatment Approaches in >3L *(M. Hutchings)*
- Oral Abstract Presentations

12:15-13:00 **Best of ISHL14**

- Best of ISHL14 *(R. Advani)*
- Farewell *(P. Borchmann)*

Meeting adjourns

08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00

Scientific Sessions/Main Program
Workshop
Scientific Symposia

Version 26/09-09

SPONSORS

We thank the following pharmaceutical companies
for supporting ISHL14:

PLATIN

Takeda Pharmaceuticals USA, Inc. | www.takeda.com

Bristol Myers Squibb

Bristol Myers Squibb | www.bms.com

Miltenyi Biomedicine

Miltenyi Biomedicine GmbH | www.miltenyibiomedicine.com

SILVER

MSD

MSD Sharp & Dohme GmbH | www.msd.de

BRONZE

BeOne

BeOne Medicines Germany GmbH |
www.beonemedicines.de

natera

Natera, Inc.| www.natera.com